HOXB7 promotes malignant progression by activating the TGF-{beta} signaling pathway

Overexpression of HOXB7 in breast cancer cells induces an epithelial-mesenchymal transition (EMT) and promotes tumor progression and lung metastasis. However, the underlying mechanisms for HOXB7-induced aggressive phenotypes in breast cancer remain largely unknown. Here we report that phosphorylation of SMAD3 is detected in a higher percentage in primary mammary tumor tissues from double transgenic MMTV-HOXB7/Her2 mice than tumors from single transgenic Her2/neu mice, suggesting activation of TGF-β/SMAD3 signaling by HOXB7 in breast tumor tissues. As predicted, TGF-β2 was high in four mouse Her2xHOXB7 transgenic mouse tumor cell lines and two breast cancer cell lines transfected with HOXB7, while TGF-β2 was low in HOXB7-depleted cells. HOXB7 directly bound to, and activated the TGF-β2 promoter in luciferase and chromatin-immunoprecipitation assays. Increased migration and invasion as a result of HOXB7 overexpression in breast cancer cells was reversed by knockdown of TGF-β2 or pharmacologic inhibition of TGF-β signaling. Further, knockdown of TGF-β2 in HOXB7-overexpressing MDA-MB-231 breast cancer cells dramatically inhibited metastasis to the lung. Interestingly, HOXB7 overexpression also induced tumor associated macrophage (TAM) recruitment and acquisition of an M2 tumor-promoting phenotype. TGF-β2 mediated HOXB7-induced activation of macrophages, suggesting that TAMs may contribute to HOXB7-promoted tumor metastasis. Providing clinical relevance to these findings, by real-time PCR analysis, there was a strong correlation between HOXB7 and TGF-β2 expression in primary breast carcinomas. Taken together, our results suggest that HOXB7 promotes tumor progression in a cell autonomous and non-cell autonomous manner through activation of the TGF-β signaling pathway.